NDLI: Vascular endothelial growth factor pathway.

Please wait, while we are loading the content...

Vascular endothelial growth factor pathway.

Content Provider	Semantic Scholar
Author	Krupitskaya, Yelena Wakelee, Heather A.
Copyright Year	2009
Abstract	New blood vessel formation (angiogenesis) is essential for the processes of tumor growth, invasion, and metastatic dissemination,1 and agents that inhibit this pathway, such as bevacizumab, have proven anticancer activity.2 Interactions between tumorand stroma-produced vascular endothelial growth factor (VEGF) ligands (particularly VEGF-A) and receptors (particularly VEGF receptor [VEGFR] 2) are central to angiogenesis and vessel permeability.3 VEGF-A also interacts with VEGFR1 expressed on endothelial cells, macrophage-lineage cells, and some tumor cells, assisting in angiogenesis and promoting direct tumor growth, metastasis, and inflammation.4 VEGFR3 is critical for lymphangiogenesis.5 Targeting the VEGF pathway inhibits vasculogenesis and tumor progression and is also thought to transiently normalize the tumor vascular supply, resulting in improved drug delivery when used in combination regimens.6 Drugs targeting the VEGF pathway7 that were discussed at the 9th annual targeted therapies meeting in Santa Monica are described below.
Starting Page	511
Ending Page	514
Page Count	4
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://core.ac.uk/download/pdf/81197827.pdf
PubMed reference number	19861922v1
Alternate Webpage(s)	https://doi.org/10.1097/01.JTO.0000361755.32660.a1
DOI	10.1097/01.jto.0000361755.32660.a1
Journal	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Volume Number	4
Issue Number	11
Language	English
Access Restriction	Open
Subject Keyword	Adverse reaction to drug Biological Markers Blood Vessel Drug Delivery Systems Endothelial Growth Factors Ligands Neoplasms Non-Small Cell Lung Carcinoma Patients Promotion (action) Protein Tyrosine Kinase Stroma Tumor Progression Vascular Endothelial Growth Factor Receptor bevacizumab cellular targeting vasculogenesis
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.

Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth.

Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer

Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.

Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.

Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.

HER1/EGFR targeting: refining the strategy.

Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.

Fine-tuning the angiogenic response to vascular endothelial growth factor.

Vascular endothelial growth factor pathway.

Similar Documents

The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.

Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth.

Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer

Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.

Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo.

Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.

HER1/EGFR targeting: refining the strategy.

Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.

Fine-tuning the angiogenic response to vascular endothelial growth factor.

Vascular endothelial growth factor pathway.